Trial Profile
Phase I Trial of rhIL-12 and rHuIFN-a2b in Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2013
Price :
$35
*
At a glance
- Drugs Interferon alpha-2b (Primary) ; Interleukin-12 (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Adverse reactions
- 08 Aug 2005 New trial record.